The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes
- 作者: Shestakova E.A.1,2, Nosova A.V.1, Dzgoeva F.K.1, Nurmamedova S.A.1, Frolkova N.V.1, Mishina E.E.1, Shestakova M.V.1
-
隶属关系:
- Endocrinology Research Centre
- Russian Medical Academy of Continuous Professional Education
- 期: 卷 97, 编号 10 (2025): Issues of endocrinology
- 页面: 859-866
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/351372
- DOI: https://doi.org/10.26442/00403660.2025.10.203462
- ID: 351372
如何引用文章
全文:
详细
Background. Despite the variety of antidiabetic therapies, many patients with type 2 diabetes (T2D) do not achieve optimal glycemic control. Therefore, there is a need to develop additional methods for managing T2D, including ones that regulate the gut microbiome.
Aim. To assess the effect of AntiAGE-Biom probiotic on metabolic parameters in T2D patients during 3 months of therapy.
Materials and methods. A randomized, double-blind, placebo-controlled, single-center study included patients with T2D with glycated hemoglobin – HbA1c<7,5% on stable antidiabetic therapy. Patients were randomized into groups receiving AntiAGE-Biom and placebo. The primary endpoint was the change in HbA1c from baseline, secondary endpoints included the dynamics in biochemical and anthropometric parameters, body composition, as well as HOMA-IR index.
Results. The study included 40 patients with T2D (n=20 in each group). There was a trend towards a decrease in HbA1c in AntiAGE-Biom group, that did not reach statistical significance. The use of the probiotic improved the body composition after 3 months: reduced the percentage of fat in men and a subgroup of patients with an initial HbA1c≥ 6.5%; also increased skeletal muscle mass and lean mass in the trunk segment in men (р<0,05).
Conclusion. AntiAGE-Biom probiotic helps to maintain metabolic control and significantly improve body composition in T2D patients with initial HbA1c<7.5%.
作者简介
Ekaterina Shestakova
Endocrinology Research Centre; Russian Medical Academy of Continuous Professional Education
编辑信件的主要联系方式.
Email: katiashestakova@mail.ru
ORCID iD: 0000-0001-6612-6851
д-р мед. наук, гл. науч. сотр., проф. каф. эндокринологии
俄罗斯联邦, Moscow; MoscowAnastasiia Nosova
Endocrinology Research Centre
Email: katiashestakova@mail.ru
ORCID iD: 0009-0002-4590-644X
врач-диетолог
俄罗斯联邦, MoscowFatima Dzgoeva
Endocrinology Research Centre
Email: katiashestakova@mail.ru
ORCID iD: 0000-0002-7314-9063
канд. мед. наук, зав. отд. по оказанию диетологической помощи
俄罗斯联邦, MoscowSabina Nurmamedova
Endocrinology Research Centre
Email: katiashestakova@mail.ru
ORCID iD: 0009-0002-7153-6681
ординатор-диетолог
俄罗斯联邦, MoscowNadezhda Frolkova
Endocrinology Research Centre
Email: katiashestakova@mail.ru
ORCID iD: 0009-0001-6204-4231
аспирант
俄罗斯联邦, MoscowEkaterina Mishina
Endocrinology Research Centre
Email: katiashestakova@mail.ru
ORCID iD: 0000-0002-5371-8708
канд. мед. наук, науч. сотр.
俄罗斯联邦, MoscowMarina Shestakova
Endocrinology Research Centre
Email: katiashestakova@mail.ru
ORCID iD: 0000-0002-5057-127X
акад. РАН, д-р мед. наук, проф., дир. Института диабета, зам. дир.
俄罗斯联邦, Moscow参考
- Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 12-й выпуск. М. 2025 [Dedov II, Shestakova MV, Maiorov AIu, et al. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. II Dedova, MV Shestakovoi, AIu Maiorova. 12-i vypusk. Moscow. 2025 (in Russian)].
- Park HY, Lee HB, Lee SY, et al. Lactococcus lactis KF140 Reduces Dietary Absorption of N(ε) – (Carboxymethyl)lysine in Rats and Humans via β-Galactosidase Activity. Front Nutr. 2022;9:916262. doi: 10.3389/fnut.2022.916262
- Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104-23 [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-23 (in Russian)]. doi: 10.14341/dm13035
- Green M, Arora K, Prakash S. Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. Int J Mol Sci. 2020;21(8):2890. doi: 10.3390/ijms21082890
- Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-6.e7. doi: 10.1053/j.gastro.2012.06.031
- Покровская Е.В., Жгун Е.С., Шестакова Е.А., и др. Трансплантация фекальной микробиоты в составе комплексной терапии сахарного диабета у сибсов с ожирением: клинический случай. Сахарный диабет. 2022;25(4):405-17 [Pokrovskaya EV, Zhgun ES, Shestakova EA, et al. Feсal microbiota transplantation in the format of complex therapy in obesive siblings: clinical case. Diabetes Mellitus. 2022;25(4):405-17 (in Russian)]. doi: 10.14341/dm12893
- Kocsis T, Molnár B, Németh D, et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Sci Rep. 2020;10(1):11787. doi: 10.1038/s41598-020-68440-1
- Cuthill S, Muroke V, Dubois A, et al. Effect of probiotic supplementation on glycemic control in patients with type 2 diabetes: A randomized controlled trial. Clin Nutr ESPEN. 2025;68:148-52. doi: 10.1016/j.clnesp.2025.05.013
- Paquette S, Thomas SC, Venkataraman K, et al. The Effects of Oral Probiotics on Type 2 Diabetes Mellitus (T2DM): A Clinical Trial Systematic Literature Review. Nutrients. 2023;15(21):4690. doi: 10.3390/nu15214690
补充文件







